Ignite Creation Date:
2025-12-24 @ 7:57 PM
Ignite Modification Date:
2025-12-25 @ 5:32 PM
Study NCT ID:
NCT06558604
Status:
RECRUITING
Last Update Posted:
2025-01-27
First Post:
2024-07-24
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Phase II Study Evaluating Glofitamab in Combination With Venetoclax Plus Zanubrutinib or Venetoclax Alone in Subjects With Untreated or Relapsed/Refractory High-risk Mantle-cell Lymphoma
Sponsor:
The Lymphoma Academic Research Organisation
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-02
Start Date Type:
ESTIMATED
Primary Completion Date:
2028-05
Primary Completion Date Type:
ESTIMATED
Completion Date:
2032-03
Completion Date Type:
ESTIMATED
First Submit Date:
2024-07-24
First Submit QC Date:
None
Study First Post Date:
2024-08-16
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-01-23
Last Update Post Date:
2025-01-27
Last Update Post Date Type:
ACTUAL